Is ARQT or ASBP more undervalued in 2026?

CirclFi compares Arcutis Biotherapeutics, Inc. (ARQT) and Aspire Biopharma Holdings, Inc. (ASBP) using 13 institutional-grade valuation models. ARQT has a Quality of Company score of 6.2/10 while ASBP scores 4.6/10.

Which is a better buy — ARQT or ASBP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ARQT and ASBP valuations compare?

ARQT at $21.44 and ASBP at $5.53 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ARQT vs ASBP Valuation Comparison 2026 — Intrinsic Value Analysis

ARQT

Biotechnology

Arcutis Biotherapeutics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$21.44

Last close

Models

13/13

Active

ASBP

Biotechnology

Aspire Biopharma Holdings, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$5.53

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	ARQT Fair Value	ARQT Upside	ASBP Fair Value	ASBP Upside
Bayesian DCF	Intrinsic	$6.25	-70.9%	$3.92	-29.0%
Earnings Power Value	Intrinsic	$3.91	-83.3%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$21.15	-1.4%	$7.61	+37.6%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARQT vs ASBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARQT vs ASBP — Which Stock Is More Undervalued?

ARQT scores higher with a 6.2/10 quality rating vs ASBP's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Arcutis Biotherapeutics, Inc. (ARQT) and Aspire Biopharma Holdings, Inc. (ASBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARQT currently trades at $21.44 with a QOC of 6.2/10, while ASBP trades at $5.53 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).